Antiphospholipid Syndrome (APS) is a thrombophilic disorder causing recurrent venous and arterial thrombosis requiring longterm anticoagulation. This is a Case Report of a patient on adequate coumadin therapy who developed venous and arterial thrombosis and the subsequent dilemma in clinical management.
INTRODUCTION
Antiphospholipid Syndrome (APS) is a thrombophilic disorder causing recurrent venous and arterial thrombosis requiring long-term anticoagulation. This is a Case Report of a patient on adequate coumadin therapy who developed venous and arterial thrombosis and the subsequent dilemma in clinical management.
CASE PRESENTATION
A 51 year old Jamaican woman with Systemic Lupus Erythematosis (SLE) presented to the Emergency Department complaining of painful swelling and purple discoloration of her left hand for 3 days. She gave no history of trauma or fever. Her SLE was complicated by antiphospholipid syndrome and stage III lupus nephritis. She was on coumadin therapy for a left ventricular thrombus diagnosed 2 years prior to this admission, and had a 10 packyear smoking history.
On examination, she was afebrile and in moderate distress due to pain. Pulses were felt equally in the brachial, radial and ulnar arteries. Her left hand was swollen, warm, cyanotic and tender. This case illustrates an uncommon case of recurrent venous and arterial thromboses in a coumadin treated APS patient. There is no consensus regarding the management of recurrent thromboses in patients on coumadin therapy ( 4 ). Debate continues over the benefits and risks of low molecular weight heparin vs. high intensity coumadin therapy. Published data, mostly from small retrospective studies, support one or the other ( 5 ). Prospective trials are difficult due to the low prevalence of such cases and the need for long-term follow-up. Contrary to previous studies, a recent prospective double-blind trial found that high intensity coumadin was no more effective than moderate intensity coumadin in prevention of recurrent thrombosis in APS patients ( 6 ). High intensity therapy is arbitrarily used by some rheumatologists in patients at high risk. Clinical studies confirm no increased risk of bleeding complications among patients on high intensity coumadin therapy ( 7 ).
One small retrospective study showed that four of five patients on heparin developed recurrent thrombosis ( 5 ). A limited number of pilot studies suggest that treatment with antiplatelet therapy might be an alternative to coumadin ( 8 ).
Intravenous immunoglobulins have been show to be successful in treating pregnancy related complications of APS ( 9 ). These results cannot be extrapolated to clinical practice.
Management of recurrent thrombosis in APS is challenging and based on few retrospective trials or unsupported expert opinions. Further clinical trials are required to guide clinical practice in the future.
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